

Oncology Today with Dr Neil Love: Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the Phase I/II ZUMA-1 trial investigating axicabtagene ciloleucel for refractory large B-cell lymphomas?**
  - a. It included patients with a history of CNS involvement
  - b. It demonstrated an objective response rate of approximately 80% and a complete response rate higher than 50%**
  - c. No Grade 5 adverse events were reported
- 2. Emerging data evaluating CD19-targeted chimeric antigen receptor (CAR) T cells with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia have recorded which of the following outcomes?**
  - a. Good efficacy with high severity of cytokine release syndrome (CRS)
  - b. Good efficacy with low severity of CRS**
- 3. Which of the following statements is true regarding the management of severe CRS in patients receiving CAR T-cell therapy?**
  - a. Tocilizumab is the only effective agent
  - b. Corticosteroids are the only effective therapy
  - c. Both tocilizumab and corticosteroids have demonstrated efficacy**
- 4. The neurotoxicity associated with CAR T-cell therapy is typically characterized by which of the following features?**
  - a. It occurs during or after CRS, with no changes on brain MRI, in the majority of patients**
  - b. It occurs before CRS, with changes on a brain MRI, in the majority of patients